Selected research
Industry Growth & Trends
Global Human iPSCs Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Human iPSCs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Human iPSCs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Human iPSCs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Human iPSCs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Human iPSCs market include Sumitomo Dainippon Pharma, ReproCELL, Pluricell Biotech, Ncardia, Fujifilm Holding Corporation (CDI), Fate Therapeutics, Inc, Cell Inspire Biotechnology and Astellas Pharma Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Human iPSCs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Human iPSCs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Human iPSCs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Human iPSCs.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Human iPSCs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Human iPSCs Market by Company
Sumitomo Dainippon Pharma
ReproCELL
Pluricell Biotech
Ncardia
Fujifilm Holding Corporation (CDI)
Fate Therapeutics, Inc
Cell Inspire Biotechnology
Astellas Pharma Inc
Human iPSCs Segment by Type
Skin
Blood Cells
Human iPSCs Segment by Application
Regenerative Medicine
Drug Development and Discovery
Academic Research
Toxicity Screening
Others
Human iPSCs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human iPSCs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human iPSCs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human iPSCs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Human iPSCs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Skin
- Blood Cells
Applications
- Regenerative Medicine
- Drug Development and Discovery
- Academic Research
- Toxicity Screening
- Others
Companies covered
- Sumitomo Dainippon Pharma
- ReproCELL
- Pluricell Biotech
- Ncardia
- Fujifilm Holding Corporation (CDI)
- Fate Therapeutics, Inc
- Cell Inspire Biotechnology
- Astellas Pharma Inc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Human iPSCs Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Human iPSCs Market Size by Region (2021-2032)
- 1.4.1 Global Human iPSCs Market Size by Region (2021-2026)
- 1.4.2 Global Human iPSCs Market Size by Region (2027-2032)
- 1.5 Key Regions Human iPSCs Market Size (2021-2032)
- 1.5.1 North America Human iPSCs Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Human iPSCs Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Human iPSCs Market Size Growth Rate (2021-2032)
- 1.5.4 South America Human iPSCs Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Human iPSCs Market Size Growth Rate (2021-2032)
2 Human iPSCs Market by Type
- 2.1 Type Introduction
- 2.1.1 Skin
- 2.1.2 Blood Cells
- 2.2 Global Human iPSCs Market Size by Type
- 2.2.1 Global Human iPSCs Market Size Overview by Type (2021-2032)
- 2.2.2 Global Human iPSCs Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Human iPSCs Market Size Forecasted by Type (2027-2032)
- 2.3 Global Human iPSCs Market Size by Regions
- 2.3.1 North America Human iPSCs Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Human iPSCs Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Human iPSCs Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Human iPSCs Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Human iPSCs Market Size Breakdown by Type (2021-2026)
3 Human iPSCs Market by Application
- 3.1 Type Introduction
- 3.1.1 Regenerative Medicine
- 3.1.2 Drug Development and Discovery
- 3.1.3 Academic Research
- 3.1.4 Toxicity Screening
- 3.1.5 Others
- 3.2 Global Human iPSCs Market Size by Application
- 3.2.1 Global Human iPSCs Market Size Overview by Application (2021-2032)
- 3.2.2 Global Human iPSCs Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Human iPSCs Market Size Forecasted by Application (2027-2032)
- 3.3 Global Human iPSCs Market Size by Regions
- 3.3.1 North America Human iPSCs Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Human iPSCs Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Human iPSCs Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Human iPSCs Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Human iPSCs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Human iPSCs Industry Trends
- 4.2 Human iPSCs Industry Drivers
- 4.3 Human iPSCs Industry Opportunities and Challenges
- 4.4 Human iPSCs Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Human iPSCs Revenue (2021-2026)
- 5.2 Global Human iPSCs Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Human iPSCs Key Company Headquarters & Area Served
- 5.4 Global Human iPSCs Company, Product Type & Application
- 5.5 Global Human iPSCs Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Human iPSCs Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Human iPSCs Players Market Share by Revenue in 2025
- 5.6.3 2025 Human iPSCs Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Sumitomo Dainippon Pharma
- 6.1.1 Sumitomo Dainippon Pharma Company Information
- 6.1.2 Sumitomo Dainippon Pharma Business Overview
- 6.1.3 Sumitomo Dainippon Pharma Human iPSCs Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Sumitomo Dainippon Pharma Human iPSCs Product Portfolio
- 6.1.5 Sumitomo Dainippon Pharma Recent Developments
- 6.2 ReproCELL
- 6.2.1 ReproCELL Company Information
- 6.2.2 ReproCELL Business Overview
- 6.2.3 ReproCELL Human iPSCs Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 ReproCELL Human iPSCs Product Portfolio
- 6.2.5 ReproCELL Recent Developments
- 6.3 Pluricell Biotech
- 6.3.1 Pluricell Biotech Company Information
- 6.3.2 Pluricell Biotech Business Overview
- 6.3.3 Pluricell Biotech Human iPSCs Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Pluricell Biotech Human iPSCs Product Portfolio
- 6.3.5 Pluricell Biotech Recent Developments
- 6.4 Ncardia
- 6.4.1 Ncardia Company Information
- 6.4.2 Ncardia Business Overview
- 6.4.3 Ncardia Human iPSCs Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Ncardia Human iPSCs Product Portfolio
- 6.4.5 Ncardia Recent Developments
- 6.5 Fujifilm Holding Corporation (CDI)
- 6.5.1 Fujifilm Holding Corporation (CDI) Company Information
- 6.5.2 Fujifilm Holding Corporation (CDI) Business Overview
- 6.5.3 Fujifilm Holding Corporation (CDI) Human iPSCs Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Fujifilm Holding Corporation (CDI) Human iPSCs Product Portfolio
- 6.5.5 Fujifilm Holding Corporation (CDI) Recent Developments
- 6.6 Fate Therapeutics, Inc
- 6.6.1 Fate Therapeutics, Inc Company Information
- 6.6.2 Fate Therapeutics, Inc Business Overview
- 6.6.3 Fate Therapeutics, Inc Human iPSCs Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Fate Therapeutics, Inc Human iPSCs Product Portfolio
- 6.6.5 Fate Therapeutics, Inc Recent Developments
- 6.7 Cell Inspire Biotechnology
- 6.7.1 Cell Inspire Biotechnology Company Information
- 6.7.2 Cell Inspire Biotechnology Business Overview
- 6.7.3 Cell Inspire Biotechnology Human iPSCs Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Cell Inspire Biotechnology Human iPSCs Product Portfolio
- 6.7.5 Cell Inspire Biotechnology Recent Developments
- 6.8 Astellas Pharma Inc
- 6.8.1 Astellas Pharma Inc Company Information
- 6.8.2 Astellas Pharma Inc Business Overview
- 6.8.3 Astellas Pharma Inc Human iPSCs Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Astellas Pharma Inc Human iPSCs Product Portfolio
- 6.8.5 Astellas Pharma Inc Recent Developments
7 North America
- 7.1 North America Human iPSCs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Human iPSCs Market Size by Country (2021-2026)
- 7.3 North America Human iPSCs Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Human iPSCs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Human iPSCs Market Size by Country (2021-2026)
- 8.3 Europe Human iPSCs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Human iPSCs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Human iPSCs Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Human iPSCs Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Human iPSCs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Human iPSCs Market Size by Country (2021-2026)
- 10.3 South America Human iPSCs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Human iPSCs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Human iPSCs Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Human iPSCs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst